{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:41:40Z","timestamp":1776163300554,"version":"3.50.1"},"reference-count":40,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>CE Information<\/jats:title>\n               <jats:p>Activity Available Online: To access the article and evaluation online, go to https:\/\/www.highmarksce.com\/mscare.<\/jats:p>\n               <jats:p>Target Audience: The target audience for this activity is physicians, advanced practice clinicians, nursing professionals, pharmacists, and other health care providers involved in the management of patients with multiple sclerosis (MS).<\/jats:p>\n               <jats:p>Learning Objectives: Recognize the frequency of utilization of non-DMT medications by MS patients and integrate questions about their use into patient history. Characterize and be mindful of the out-of-pocket cost burden of DMT and non-DMT medication use in patients with MS.<\/jats:p>\n               <jats:p>Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Intellisphere, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.<\/jats:p>\n               <jats:p>This activity was planned by and for the health care team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.<\/jats:p>\n               <jats:p>For Physicians: The Consortium of Multiple Sclerosis Centers designates this journal-based activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)\u2122. Physicians should claim only the credit commensurate with the extent of their participation in the activity.<\/jats:p>\n               <jats:p>For Nurses: This activity is awarded 0.5 contact hours of nursing continuing professional development (NCPD) (0.5 of these credits are in the area of pharmacology).<\/jats:p>\n               <jats:p>For Pharmacists: This knowledge-based activity (UAN JA4008165-9999-22-020-H01-P) qualifies for 0.5 contact hours (0.05 CEUs) of continuing pharmacy education credit.<\/jats:p>\n               <jats:p>For Physician Assistants: The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until April 1, 2023. PAs should only claim credit commensurate with the extent of their participation.<\/jats:p>\n               <jats:p>It is the policy of the Consortium of Multiple Sclerosis Centers to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity. For this activity, all relevant disclosures have been mitigated.<\/jats:p>\n               <jats:p>Disclosures: Francois Bethoux, MD, editor in chief of the International Journal of MS Care (IJMSC), has served as Physician Planner for this activity. He has disclosed no relevant financial relationships. Alissa Mary Willis, MD, Associate Editor of IJMSC, has disclosed no relevant financial relationships. Daniel Hartung, PharmD, MPH, consults for the National Multiple Sclerosis Society and Sandoz Pharmaceuticals. Leorah Freeman, MD, PhD, has served as a consultant for Genentech, Celgene\/Bristol Myers Squibb, EMD Serono, TG Therapeutics, and Novartis; and has received grant\/program support from EMD Serono and Genentech.<\/jats:p>\n               <jats:p>The staff at IJMSC, CMSC, and Intellisphere, LLC who are in a position to influence content have disclosed no relevant financial relationships. Laurie Scudder, DNP, NP, Continuing Education Director CMSC, has served as a planner and reviewer for this activity. She has disclosed no relevant financial relationships.<\/jats:p>\n               <jats:p>Method of Participation:<\/jats:p>\n               <jats:p>Release Date: April 1, 2022; Valid for Credit through: April 1, 2023<\/jats:p>\n               <jats:p>In order to receive CE credit, participants must: (1) Review the continuing education information, including learning objectives and author disclosures.(2) Study the educational content.(3) Complete the evaluation, which is available at https:\/\/www.highmarksce.com\/mscare.<\/jats:p>\n               <jats:p>Statements of Credit are awarded upon successful completion of the evaluation. There is no fee to participate in this activity.<\/jats:p>\n               <jats:p>Disclosure of Unlabeled Use: This educational activity may contain discussion of published and\/or investigational uses of agents that are not approved by the FDA. The CMSC and Intellisphere, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC or Intellisphere, LLC.<\/jats:p>\n               <jats:p>Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients\u2019 conditions, considering possible contraindications or risks, reviewing any applicable manufacturer\u2019s product information, and comparing any therapeutic approach with the recommendations of other authorities.<\/jats:p>","DOI":"10.7224\/1537-2073.2021-062","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T10:17:03Z","timestamp":1649931423000},"page":"90-97","source":"Crossref","is-referenced-by-count":9,"title":["Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population"],"prefix":"10.7224","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-773X","authenticated-orcid":false,"given":"Daniel M.","family":"Hartung","sequence":"first","affiliation":[{"name":"From the College of Pharmacy, Oregon State University, Portland, OR, USA (DMH, KAJ, JCM)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirbee A.","family":"Johnston","sequence":"additional","affiliation":[{"name":"From the College of Pharmacy, Oregon State University, Portland, OR, USA (DMH, KAJ, JCM)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessina C.","family":"McGregor","sequence":"additional","affiliation":[{"name":"From the College of Pharmacy, Oregon State University, Portland, OR, USA (DMH, KAJ, JCM)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis N.","family":"Bourdette","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oregon Health & Science University, Portland, OR, USA (DNB)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"issue":"13","key":"2022041421472580500_i1537-2073-24-2-90-b1","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1056\/nejm200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med."},{"issue":"1","key":"2022041421472580500_i1537-2073-24-2-90-b2","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.18553\/jmcp.2013.19.s1.S41","article-title":"Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies","volume":"19","author":"Owens","year":"2013","journal-title":"J Manag Care Pharm."},{"issue":"5","key":"2022041421472580500_i1537-2073-24-2-90-b3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3111\/13696998.2013.778268","article-title":"The cost burden of multiple sclerosis in the United States: a systematic review of the literature","volume":"16","author":"Adelman","year":"2013","journal-title":"J Med Econ."},{"key":"2022041421472580500_i1537-2073-24-2-90-b4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.msard.2019.02.006","article-title":"Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis","volume":"30","author":"Kim","year":"2019","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"2022041421472580500_i1537-2073-24-2-90-b5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler J."},{"issue":"17","key":"2022041421472580500_i1537-2073-24-2-90-b6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/wnl.0000000000005345","article-title":"Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology."},{"issue":"17","key":"2022041421472580500_i1537-2073-24-2-90-b7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/wnl.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae -Grant","year":"2018","journal-title":"Neurology."},{"issue":"21","key":"2022041421472580500_i1537-2073-24-2-90-b8","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1212\/wnl.0000000000001608","article-title":"The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?","volume":"84","author":"Hartung","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"2022041421472580500_i1537-2073-24-2-90-b9","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/jamaneurol.2019.2711","article-title":"Trends in prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis in Medicare Part D","volume":"76","author":"San-Juan-Rodriguez","year":"2019","journal-title":"JAMA Neurol."},{"issue":"2","key":"2022041421472580500_i1537-2073-24-2-90-b10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1377\/hlthaff.2018.05357","article-title":"Trends in coverage for disease-modifying therapies for multiple sclerosis in Medicare Part D","volume":"38","author":"Hartung","year":"2019","journal-title":"Health Affairs."},{"issue":"22","key":"2022041421472580500_i1537-2073-24-2-90-b11","doi-asserted-by":"publisher","first-page":"e2604","DOI":"10.1212\/wnl.0000000000007564","article-title":"Out-of-pocket costs are on the rise for commonly prescribed neurologic medications","volume":"92","author":"Callaghan","year":"2019","journal-title":"Neurology."},{"issue":"1","key":"2022041421472580500_i1537-2073-24-2-90-b12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1682\/jrrd.2004.09.0122","article-title":"Veterans Health Administration multiple sclerosis surveillance registry: the problem of case-finding from administrative databases","volume":"43","author":"Culpepper","year":"2006","journal-title":"J Rehabil Res Dev."},{"issue":"12","key":"2022041421472580500_i1537-2073-24-2-90-b13","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/jgs.15576","article-title":"Medicare\u2019s variation in out-of-pocket costs for prescriptions: the irrational examples of in-hospital observation and home infusion","volume":"66","author":"Wright","year":"2018","journal-title":"J Am Geriatr Soc."},{"issue":"5","key":"2022041421472580500_i1537-2073-24-2-90-b14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7224\/1537-2073.2014-076","article-title":"Medications are associated with falls in people with multiple sclerosis: a prospective cohort study","volume":"17","author":"Cameron","year":"2015","journal-title":"Int J MS Care."},{"issue":"7","key":"2022041421472580500_i1537-2073-24-2-90-b15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/1352458517731912","article-title":"Medication usage and falls in people with multiple sclerosis","volume":"24","author":"Comber","year":"2018","journal-title":"Mult Scler."},{"issue":"11","key":"2022041421472580500_i1537-2073-24-2-90-b16","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/jamaneurol.2019.2445","article-title":"Addressing the rising prices of disease-modifying therapies for multiple sclerosis","volume":"76","author":"Hartung","year":"2019","journal-title":"JAMA Neurol."},{"issue":"4","key":"2022041421472580500_i1537-2073-24-2-90-b17","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s13311-017-0566-3","article-title":"Economics and cost-effectiveness of multiple sclerosis therapies in the USA","volume":"14","author":"Hartung","year":"2017","journal-title":"Neurotherapeutics."},{"key":"2022041421472580500_i1537-2073-24-2-90-b18","unstructured":"Cubanski\n              J,\n            \n            \n              Koma\n              W,\n            \n            \n              Neuman\n              T.\n            \n          \n          The out-of-pocket cost burden for specialty drugs in Medicare Part D in 2019.\n\t\t\t\t\t2019.\n\t\t\t\t\tAccessed February 1, 2019. http:\/\/files.kff.org\/attachment\/Issue-Brief-the-Out-of-Pocket-Cost-Burden-for-Specialty-Drugs-in-Medicare-Part-D-in-2019"},{"key":"2022041421472580500_i1537-2073-24-2-90-b19","unstructured":"Hoadley\n              J,\n            \n            \n              Summer\n              L,\n            \n            \n              Hargrave\n              E,\n            \n            \n              Cubanski\n              J,\n            \n            \n              Neuman\n              T.\n            \n          \n          Medicare Part D in its ninth year: the 2014 marketplace and key trends, 2006\u20132014.\n\t\t\t\t\tAugust 18, 2014. Accessed June 29, 2020. https:\/\/www.kff.org\/medicare\/report\/medicare-part-d-in-its-ninth-year-the-2014-marketplace-and-key-trends-2006-2014\/"},{"issue":"suppl 1","key":"2022041421472580500_i1537-2073-24-2-90-b20","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1111\/1475-6773.12744","article-title":"Impact of cost-sharing increases on continuity of specialty drug use: a quasi-experimental study","volume":"53","author":"Li","year":"2018","journal-title":"Health Serv Res."},{"issue":"8","key":"2022041421472580500_i1537-2073-24-2-90-b21","first-page":"460","article-title":"Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis","volume":"18","author":"Romley","year":"2012","journal-title":"Am J Manag Care."},{"issue":"9","key":"2022041421472580500_i1537-2073-24-2-90-b22","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jval.2017.10.025","article-title":"Cost sharing of disease-modifying treatments (DMTs) as policy lever to improve DMTs\u2019 access in multiple sclerosis","volume":"21","author":"Shao","year":"2018","journal-title":"Value Health."},{"key":"2022041421472580500_i1537-2073-24-2-90-b23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1108\/s0731-2199(2010)0000022011","article-title":"Cost sharing, benefit design, and adherence: the case of multiple sclerosis","volume":"22","author":"Dor","year":"2010","journal-title":"Adv Health Econ Health Serv Res."},{"issue":"8","key":"2022041421472580500_i1537-2073-24-2-90-b24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.18553\/jmcp.2009.15.8.648","article-title":"Association of prescription abandonment with cost share for high-cost specialty pharmacy medications","volume":"15","author":"Gleason","year":"2009","journal-title":"J Manag Care Pharm."},{"issue":"1","key":"2022041421472580500_i1537-2073-24-2-90-b25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.msard.2014.09.214","article-title":"Therapy optimization in multiple sclerosis: a cohort study of therapy adherence and risk of relapse","volume":"4","author":"Cohen","year":"2015","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"2022041421472580500_i1537-2073-24-2-90-b26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3111\/13696998.2012.667027","article-title":"Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US","volume":"15","author":"Ivanova","year":"2012","journal-title":"J Med Econ."},{"issue":"2","key":"2022041421472580500_i1537-2073-24-2-90-b27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","article-title":"Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study","volume":"30","author":"Steinberg","year":"2010","journal-title":"Clin Drug Investig."},{"issue":"6","key":"2022041421472580500_i1537-2073-24-2-90-b28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3111\/13696998.2011.618517","article-title":"The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate","volume":"14","author":"Oleen-Burkey","year":"2011","journal-title":"J Med Econ."},{"issue":"1","key":"2022041421472580500_i1537-2073-24-2-90-b29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv Ther."},{"key":"2022041421472580500_i1537-2073-24-2-90-b30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/ceor.S130334","article-title":"Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis","volume":"9","author":"Burks","year":"2017","journal-title":"Clinicoecon Outcomes Res."},{"key":"2022041421472580500_i1537-2073-24-2-90-b31","volume-title":"Decisional Dilemmas in Discontinuing Prolonged Disease-Modifying Treatment for Multiple Sclerosis","author":"Butler","year":"2015"},{"issue":"6","key":"2022041421472580500_i1537-2073-24-2-90-b32","first-page":"s151","article-title":"Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management","volume":"22","author":"Owens","year":"2016","journal-title":"Am J Manag Care."},{"issue":"13","key":"2022041421472580500_i1537-2073-24-2-90-b33","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1056\/NEJMp1301993","article-title":"Prescription-drug coupons: no such thing as a free lunch","volume":"369","author":"Ross","year":"2013","journal-title":"N Engl J Med."},{"key":"2022041421472580500_i1537-2073-24-2-90-b34","author":"Charitable assistance in Medicare Part D.","year":"2020"},{"issue":"13","key":"2022041421472580500_i1537-2073-24-2-90-b35","doi-asserted-by":"publisher","first-page":"e1407","DOI":"10.1212\/wnl.0000000000008936","article-title":"Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis","volume":"94","author":"Hartung","year":"2020","journal-title":"Neurology."},{"issue":"9","key":"2022041421472580500_i1537-2073-24-2-90-b36","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamainternmed.2020.2771","article-title":"US spending associated with transition from daily to 3-times-weekly glatiramer acetate","volume":"180","author":"Rome","year":"2020","journal-title":"JAMA Intern Med."},{"issue":"4","key":"2022041421472580500_i1537-2073-24-2-90-b37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1212\/CPJ.0000000000000929","article-title":"Closing the Part D coverage gap and out-of-pocket costs for multiple sclerosis drugs","volume":"11","author":"Hartung","year":"2021","journal-title":"Neurol Clin Pract."},{"issue":"21","key":"2022041421472580500_i1537-2073-24-2-90-b38","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMp1802159","article-title":"Doughnuts and discounts: changes to Medicare Part D under the Bipartisan Budget Act of 2018","volume":"378","author":"Donohue","year":"2018","journal-title":"N Engl J Med."},{"key":"2022041421472580500_i1537-2073-24-2-90-b39","unstructured":"National Multiple Sclerosis Society.\n          \n          Access to MS medications.\n\t\t\t\t\tAccessed June 29, 2020. https:\/\/www.nationalmssociety.org\/NationalMSSociety\/media\/MSNationalFiles\/Advocacy\/2020-PPC-Access-to-MS-Meds-Leavebehind-DONE_1.pdf?ext=.pdf"},{"issue":"15","key":"2022041421472580500_i1537-2073-24-2-90-b40","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMp1908688","article-title":"Proposals to redesign Medicare Part D: easing the burden of rising drug prices","volume":"381","author":"Dusetzina","year":"2019","journal-title":"N Engl J Med."}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/24\/2\/90\/3045420\/i1537-2073-24-2-90.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/24\/2\/90\/3045420\/i1537-2073-24-2-90.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:13:11Z","timestamp":1752786791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/characteristics-of-prescription-drug-use-among-individuals-with-multiple-sclerosis-in-the-us-medicare-population"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,14]]},"published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2021-062","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}